Nektar Therapeutics (NKTR) Tops Q3 EPS by 1c
Tweet
Share
E-mail
Get Alerts NKTR Hot Sheet
Price: $59.38 +0.29%
EPS Growth %: +96.4%
Financial Fact:
Provision for income taxes: 139K
Today's EPS Names:
PLCE, COE, JVA, More
EPS Growth %: +96.4%
Financial Fact:
Provision for income taxes: 139K
Today's EPS Names:
PLCE, COE, JVA, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q3 EPS of ($0.19), $0.01 better than the analyst estimate of ($0.20). Revenue for the quarter came in at $24.1 million versus the consensus estimate of $21.26 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- MIND Technology (MIND) Misses Q1 EPS by 5c
- BIG3 Basketball to go public via Graf Global merger at $290 million
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
